Thermo Fisher Scientific Unveils Oncomine Comprehensive Assay Plus for Next-Day Genomic Profiling on Ion Torrent Genexus System

Thermo Fisher Scientific has introduced the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System to accelerate precision oncology research. The assay detects 517 genes and delivers comprehensive genomic profiling results in as little as one day, enabled by Ion Torrent technology and automated workflows. This solution empowers researchers to leverage more comprehensive results at a faster pace, accelerating life-saving research.

Thermo Fisher Scientific has recently introduced the Oncomine Comprehensive Assay Plus on the Ion Torrent Genexus System, marking a significant advancement in precision oncology research. The assay, which detects a broad range of genomic alterations in 517 genes, now delivers comprehensive genomic profiling (CGP) results in as little as one day, thanks to Ion Torrent technology and automated workflows. This innovation empowers researchers to leverage more comprehensive results at a faster pace, accelerating life-saving research.

The Oncomine Comprehensive Assay Plus, already available on the Ion GeneStudio S5 systems, detects single-nucleotide variants, insertions and deletions, copy number variations, and fusions. Additionally, it identifies genomic signatures such as homologous recombination deficiency (HRD), tumor mutational burden (TMB), and microsatellite instability (MSI). With the capabilities of the Genexus System, researchers can now detect these important biomarkers quickly and easily.

Hector M Alcaraz, MS, Founder of Imagene Health, SA de CV, an early access user of the Oncomine Comprehensive Assay Plus on the Genexus System, expressed enthusiasm for the new solution. "This will make CGP more accessible to our local markets so that we can drive the future of precision medicine forward," he said.

Kathy Davy, president of Clinical Next Generation Sequencing at Thermo Fisher Scientific, highlighted the importance of rapid CGP. "In recent years, new genomic insights have played an essential role in advancing our understanding of human health and driving novel drug development," she said. "The addition of the Oncomine Comprehensive Assay Plus on the Genexus System brings the benefits of rapid CGP to more labs, empowering researchers to leverage more comprehensive results at a much faster pace and accelerate what could be life-saving research."

The Genexus System is an automated and integrated NGS platform capable of delivering NGS results as soon as the next day. With end-to-end automation that requires less hands-on time, the Genexus System makes genomic profiling accessible to more researchers with varying levels of experience. Now, with the Oncomine Comprehensive Assay Plus available on the Genexus System, research teams can leverage this end-to-end solution to deliver accurate and robust CGP results as soon as the next day.

For more information about the Oncomine Comprehensive Assay Plus on the Genexus System and how this is enabling research labs to accelerate oncology research, please visit thermofisher.com/oncomine-ocaplus.

References:
[1] https://www.businesswire.com/news/home/20250714375205/en/Thermo-Fisher-Scientific-Introduces-the-Oncomine-Comprehensive-Assay-Plus-on-the-Ion-Torrent-Genexus-System-to-Help-Advance-the-Future-of-Precision-Medicine
[2] https://finance.yahoo.com/news/thermo-fisher-oncomine-dx-express-093210818.html
[3] https://www.selectscience.net/article/thermo-fisher-ngs-assay-fda-approved-as-companion-diagnostic-for-zegfrovy-and-tumor-profiling